FibroGen, Inc. (NASDAQ: FGEN) today reported financial results for the third quarter 2023 and provided an update on the Company’s recent developments.

“Today, we reported another quarter of strong roxadustat volume growth in China, achieving the highest ever value share, at 42%, in the anemia of CKD category,” said Thane Wettig, Chief Executive Officer, FibroGen. “The continued strength of our China business, sooner than expected realization of our corporate cost reduction efforts and our strong balance sheet provide us a cash runway into 2026. Over the next 12 months, we will obtain data read-outs from our two late-stage pancreatic cancer trials, start a Phase 2 metastatic castrate-resistant prostate cancer trial, and file two immuno-oncology INDs. These unique and exciting programs, combined with the quality of our talented colleagues, provide a strong foundation to create significant value for shareholders relative to our current valuation.”

Recent Developments and Key Events of Third Quarter 2023:

  • Appointed Thane Wettig as Chief Executive Officer.
  • Supplemental New Drug Application (sNDA) accepted by the China Health Authority for roxadustat for the treatment of patients with chemotherapy-induced anemia (CIA). Expect approval decision of CIA in China in mid-2024.
  • Successful implementation of cost reduction plan, now resulting in an expected reduction of total annualized expenses of $120 million.
  • Reported negative topline results from the LELANTOS-2 Phase 3 study of pamrevlumab for the treatment of ambulatory patients with Duchenne muscular dystrophy (DMD).
  • Presented Phase 3 data of roxadustat for CIA in patients with non-myeloid malignancies in an oral presentation at the European Society for Medical Oncology Congress 2023.
  • FibroGen and its partners presented five roxadustat abstracts, including four poster presentations and one late-breaker poster presentation, at the recent American Society of Nephrology (ASN) Kidney Week 2023 conference.
  • Presented preclinical data for the FG-3165 anti-Gal9 antibody program at the Society for Immunotherapy of Cancer Annual Meeting 2023.

China Performance:

  • Achieved third quarter net product revenue under U.S. GAAP from the sale of roxadustat in China of $29.4 million compared to $17.4 million in the third quarter of 2022, an increase of 69% year over year.
  • Achieved third quarter total roxadustat net sales in China1 by FibroGen and the distribution entity (JDE) jointly owned by FibroGen and AstraZeneca of $77.1 million, compared to $59.0 million in the third quarter of 2022, an increase of 31% year over year, driven by 37% growth in volume.
  • Roxadustat continues to be the number one brand based on value share in the anemia of chronic kidney disease market in China.

Upcoming Milestones:

Pamrevlumab

  • Topline data from the LAPIS Phase 3 study of pamrevlumab in locally advanced unresectable pancreatic cancer (LAPC) expected in 1Q 2024.
  • Topline data from the PanCAN Precision PromiseSM Phase 2/3 study of pamrevlumab in metastatic pancreatic cancer expected in 1H 2024.

Oncology Pipeline

  • Expect topline clinical trial results from Phase 1 monotherapy trial of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting a novel epitope on CD46 for metastatic castration-resistant prostate cancer (mCRPC) by 1Q 2024.
  • Anticipate the initiation of a Phase 2 trial of FG-3246 for mCRPC in 2H 2024.
  • Anticipate the filing of two INDs: FG-3165 (anti-Gal9 antibody) in 1Q 2024 and FG-3175 (anti-CCR8 antibody) in 2H 2024.

Financial:

  • Total revenue for the third quarter of 2023 was $40.1 million, as compared to $15.7 million for the third quarter of 2022, an increase of 155% year over year.
  • Net loss for the third quarter of 2023 was $63.6 million, or $0.65 net loss per basic and diluted share, compared to a net loss of $91.7 million, or $0.98 net loss per basic and diluted share one year ago.
  • Restructuring charge for the third quarter of 2023 was $12.6 million, or $0.13 impact to net loss per basic and diluted share, resulting from the reduction in U.S. workforce announced in July 2023.
  • At September 30, 2023, cash – defined as cash, cash equivalents, investments, and accounts receivable – was $283.0 million.
  • We expect our cash, cash equivalents, investments, and accounts receivable to be sufficient to fund our operating plans into 2026.

_________________________

1 Total roxadustat net sales in China includes sales made by the distribution entity as well as FibroGen China’s direct sales, each to its own distributors. The distribution entity jointly owned by AstraZeneca and FibroGen is not consolidated into FibroGen’s financial statements.

Conference Call and Webcast Details FibroGen will host a conference call and webcast today, Monday, November 6, 2023, at 5:00 PM Eastern Time to discuss financial results and provide a business update. Interested parties may access a live audio webcast of the conference call via the “Investor Relations” page of the Company’s website at www.fibrogen.com. To access the call by phone, please go to this link (registration link), and you will be provided with dial in details. To avoid delays, we encourage participants to dial in to the conference call fifteen minutes ahead of the scheduled start time. A replay of the webcast will also be available for a limited time at the following link (webcast replay).

About PamrevlumabPamrevlumab is a potential first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase 3 clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer. The U.S. Food and Drug Administration has granted Orphan Drug Designation, and Fast Track designation to pamrevlumab for the treatment of patients with LAPC. Pamrevlumab has demonstrated a safety and tolerability profile that has supported ongoing clinical investigation in LAPC and metastatic pancreatic cancer. Pamrevlumab is an investigational drug and not approved for marketing by any regulatory authority. For information about our pamrevlumab studies please visit www.clinicaltrials.gov.

About RoxadustatRoxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted by the China Health Authority.

Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD). Several other licensing applications for roxadustat have been submitted by partners, Astellas and AstraZeneca, to regulatory authorities across the globe, and are currently under review. Astellas and FibroGen are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in territories including Japan, Europe, Turkey, Russia, and the Commonwealth of Independent States, the Middle East, and South Africa. FibroGen and AstraZeneca are collaborating on the development and commercialization of roxadustat for the potential treatment of anemia in the U.S., China, and other markets not licensed to Astellas.

About FibroGen  FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in connective tissue growth factor (CTGF) biology and hypoxia-inducible factor (HIF) to advance innovative medicines for the treatment of unmet needs. Pamrevlumab, an anti-CTGF human monoclonal antibody, is in clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and metastatic pancreatic cancer. Roxadustat (爱瑞卓®, EVRENZO™) is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in CKD patients on dialysis and not on dialysis. Roxadustat is in clinical development for chemotherapy-induced anemia (CIA) and a Supplemental New Drug Application (sNDA) has been accepted by the China Health Authority. FibroGen recently expanded its research and development portfolio to include product candidates in oncology. For more information, please visit www.fibrogen.com.

Forward-Looking Statements This release contains forward-looking statements regarding FibroGen’s strategy, future plans and prospects, including statements regarding the company’s financial performance, the development and commercialization of the company’s product candidates, the potential safety and efficacy profile of its product candidates, and its clinical programs. These forward-looking statements include, but are not limited to, statements under the caption “Upcoming Milestones”, statements regarding the expected cost reduction savings, the statement that FibroGen expects its cash, cash equivalents, investments, and accounts receivable to be sufficient to fund its operating plans into 2026, and statements about FibroGen’s plans and objectives and typically are identified by use of terms such as “may,” “will”, “should,” “on track,” “could,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “potential,” “continue” and similar words, although some forward-looking statements are expressed differently. FibroGen’s actual results may differ materially from those indicated in these forward-looking statements due to risks and uncertainties related to the continued progress and timing of its various programs, including the enrollment and results from ongoing and potential future clinical trials, and other matters that are described in FibroGen’s Annual Report on Form 10-K for the fiscal year ended December 31, 2022, and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2023, each as filed with the Securities and Exchange Commission (SEC), including the risk factors set forth therein. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and FibroGen undertakes no obligation to update any forward-looking statement in this press release, except as required by law.

Condensed Consolidated Balance Sheets(In thousands)

  September 30, 2023     December 31, 2022  
  (Unaudited)     (1)  
Assets        
Current assets:        
Cash and cash equivalents $ 120,914     $ 155,700  
Short-term investments   130,426       266,308  
Accounts receivable, net   31,694       16,299  
Inventory   40,696       40,436  
Prepaid expenses and other current assets   40,378       14,083  
Total current assets   364,108       492,826  
             
Restricted time deposits   2,072       2,072  
Long-term investments         4,348  
Property and equipment, net   14,512       20,605  
Equity method investment in unconsolidated variable interest entity   4,534       5,061  
Operating lease right-of-use assets   71,248       79,893  
Other assets   3,952       5,282  
Total assets $ 460,426     $ 610,087  
             
Liabilities, stockholders’ equity and non-controlling interests        
Current liabilities:        
Accounts payable $ 19,220     $ 30,758  
Accrued and other liabilities   170,986       219,773  
Deferred revenue   7,325       12,739  
Operating lease liabilities, current   11,884       10,292  
Total current liabilities   209,415       273,562  
         
Product development obligations   16,942       16,917  
Deferred revenue, net of current   154,206       185,722  
Operating lease liabilities, non-current   70,035       79,593  
Senior secured term loan facilities, non-current   71,666        
Liability related to sale of future revenues, non-current   49,109       49,333  
Other long-term liabilities   4,255       6,440  
Total liabilities   575,628       611,567  
         
Redeemable non-controlling interests   21,480        
Total stockholders’ deficit attributable to FibroGen   (157,169 )     (21,447 )
Nonredeemable non-controlling interests   20,487       19,967  
Total deficit   (136,682 )     (1,480 )
Total liabilities, redeemable non-controlling interests and deficit $ 460,426     $ 610,087  
 
(1)   The condensed consolidated balance sheet amounts at December 31, 2022 are derived from audited financial statements.
 

Condensed Consolidated Statements of Operations(In thousands, except per share data)

  Three Months Ended September 30,     Nine Months Ended September 30,  
  2023     2022     2023     2022  
  (Unaudited)  
Revenue:                      
License revenue $ 2,649     $     $ 9,649     $ 22,590  
Development and other revenue   6,775       2,453       15,825       19,672  
Product revenue, net   29,390       17,359       77,439       59,495  
Drug product revenue, net   1,320       (4,077 )     17,701       4,610  
Total revenue   40,134       15,735       120,614       106,367  
                       
Operating costs and expenses:                      
Cost of goods sold   4,243       4,308       13,441       15,355  
Research and development   61,194       75,182       231,158       235,163  
Selling, general and administrative   25,573       29,902       91,029       90,722  
Restructuring charge   12,606             12,606        
Total operating costs and expenses   103,616       109,392       348,234       341,240  
Loss from operations   (63,482 )     (93,657 )     (227,620 )     (234,873 )
                       
Interest and other, net:                      
Interest expense   (5,022 )     (84 )     (10,464 )     (321 )
Interest income and other income (expenses), net   4,296       1,798       7,984       6,672  
Total interest and other, net   (726 )     1,714       (2,480 )     6,351  
                       
Loss before income taxes   (64,208 )     (91,943 )     (230,100 )     (228,522 )
Provision for (benefit from) income taxes   84       114       (77 )     250  
Investment income in unconsolidated variable interest entity   677       407       2,023       1,293  
Net loss $ (63,615 )   $ (91,650 )   $ (228,000 )   $ (227,479 )
                       
Net loss per share - basic and diluted $ (0.65 )   $ (0.98 )   $ (2.35 )   $ (2.43 )
                       
Weighted average number of common shares used to calculate net loss per share - basic and diluted   98,245       93,767       96,901       93,431  
                               

Contacts:FibroGen, Inc.

Investors:David DeLucia, CFAVice President of Corporate FP&A / Investor Relationsddelucia@fibrogen.com

Media:Meichiel KeenanDirector, Investor Relations and Corporate Communicationsmkeenan@fibrogen.com

FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more FibroGen Charts.
FibroGen (NASDAQ:FGEN)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more FibroGen Charts.